<DOC>
	<DOC>NCT00471146</DOC>
	<brief_summary>The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.</brief_summary>
	<brief_title>Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.</brief_title>
	<detailed_description>This study was prematurely discontinued for futility on 23 January 2009, based on a planned interim analysis by an independent Data Safety Monitoring Board (DSMB) that found no evidence of improvement in the primary endpoint (survival) in patients treated with axitinib and gemcitabine compared to gemcitabine alone. Enrollment on this study has been discontinued.</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Pancreatic Ductal</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically or cytologically confirmed, metastatic or locally, advanced pancreatic adenocarcinoma not amenable to curative resection. Adequate renal, hepatic and bone marrow function. Performance status 0 or 1. Prior treatment with any systemic chemotherapy for metastatic disease. Prior treatment with gemcitabine, AG013736, or other vascular endothelial growth factor inhibitors. Current or recent bleeding, thromboembolic event and or use of a thrombolytic agent. Inability to take oral medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Randomized Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For Advanced Pancreatic Cancer.</keyword>
</DOC>